Compare TG Therapeutics Inc (TGTX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while Tripadvisor Inc Common Stock trades at $8.71 (market cap $1.01B). The key difference: TG Therapeutics Inc is far larger — about 8.1× Tripadvisor Inc Common Stock's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| TGTX | TRIP | |
|---|---|---|
Market Cap | $8.16B | $1.01B |
Volume | 1,735,121 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $16.72 |
52-Week Low | $26.94 | $8.04 |
Typical Hold Time | 16 Days | 57 Days |
Enterprise Value | $8.37B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
TripAdvisor (TRIP) trades at $8.675, up 0.52% on the day, but remains near its 52-week low of $8.27 (Defense World, 2026-09-25). The stock shows a mixed technical picture with bullish oscillators but bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with net income improving to $40M, though recent quarterly earnings have missed expectations. The company faces headwinds from AI competition in travel planning but maintains strong brand recognition through its Travelers' Choice Awards.
The investment outlook is cautious. While analyst consensus suggests 56% upside to the $13.58 price target, recent insider selling and earnings misses highlight execution risks. The key opportunity lies in the potential monetization of Viator and TheFork sale, but competitive pressure from AI platforms remains a significant threat to long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
